A Randomized, Single Center, Double Blind, Two Treatment, Two-Period, Crossover Glucose Clamp Study To Test For Bioequivalence Between Wockhardtâ??s Consegnaâ?¢ - 30/70 (Bi Phasic Isophane Insulin 30/70 Injection 200 IU) and Mixtard® 30/70 (100 IU), In Healthy Subjects.

Trial Profile

A Randomized, Single Center, Double Blind, Two Treatment, Two-Period, Crossover Glucose Clamp Study To Test For Bioequivalence Between Wockhardtâ??s Consegnaâ?¢ - 30/70 (Bi Phasic Isophane Insulin 30/70 Injection 200 IU) and Mixtard® 30/70 (100 IU), In Healthy Subjects.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Insulin-lispro/Insulin-suspension-isophane (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Wockhardt Ltd
  • Most Recent Events

    • 15 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top